John Kuruvilla
Overview
Explore the profile of John Kuruvilla including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
173
Citations
4462
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kuruvilla J, Armand P, Herrera A, Ribrag V, Thieblemont C, von Tresckow B, et al.
Transplant Cell Ther
. 2025 Mar;
PMID: 40043848
Background: The safety and efficacy of allogeneic stem cell transplantation (allo-SCT) following anti-programmed cell death protein 1 (PD-1) therapy in participants with hematologic malignances is of high clinical interest. Objective:...
2.
Gopal A, Armand P, Neelapu S, Bartlett N, Spurgeon S, Kuruvilla J, et al.
Blood Adv
. 2025 Mar;
PMID: 40030000
Despite high response rates, anti-PD-1 therapy monotherapy eventually fails in most patients with relapsed or refractory Hodgkin Lymphoma (HL) and is generally ineffective in most other B-cell malignancies. The lymphocyte...
3.
Abeyakoon C, Ting E, Khan S, Maganti M, Bhella S, Crump M, et al.
Leuk Lymphoma
. 2025 Feb;
:1-5.
PMID: 39985180
No abstract available.
4.
Lee O, Kuruvilla J, Hodgson D, Veit-Haibach P, Metser U
Br J Radiol
. 2025 Feb;
PMID: 39933018
Objectives: To evaluate the diagnostic accuracy of 18F-FDG PET or PET/CT in detecting histological transformation (HT) of indolent lymphomas. Methods: A systematic search of articles up to July 2024 was...
5.
Alemu H, Pope A, Lo S, Chin-Yee N, Khorramak K, Cenizal C, et al.
J Pain Symptom Manage
. 2025 Jan;
69(4):420-427.e2.
PMID: 39828100
Context: Hematological malignancies represent a heterogeneous group of diseases with variable and often unpredictable illness trajectories. Comparisons between hematological and solid tumor malignancy referrals to an outpatient palliative care clinic...
6.
Garg V, Ruiz Buenrostro A, Heuniken K, Bagnarol R, Yousef M, Sajewicz K, et al.
Cancer Med
. 2024 Dec;
13(23):e70450.
PMID: 39651705
Background: Novel systemic anticancer therapies (SACT) in the form of targeted and immunotherapies are increasingly replacing traditional chemotherapy. Little is known about the impact of novel SACT on healthcare resource...
7.
Sehn L, Bartlett N, Matasar M, Schuster S, Assouline S, Giri P, et al.
Blood
. 2024 Oct;
145(7):708-719.
PMID: 39447094
Mosunetuzumab, a CD20×CD3 T-cell engaging bispecific antibody, redirects T cells to eliminate malignant B cells. We present updated efficacy and safety data of a pivotal phase 1/2 study after a...
8.
Kuruvilla J, Rushton C, Villa D, Aslam M, Prica A, Abdel Samad N, et al.
Br J Haematol
. 2024 Sep;
205(5):2067-2071.
PMID: 39267295
In the LY.17 randomized phase II clinical trial, adults with relapsed and refractory diffuse large B-cell lymphoma treated with ibrutinib-R-GDP (IR-GDP) for up to three cycles had more documented bacterial...
9.
Gong I, Tran D, Saibil S, Laister R, Kuruvilla J
Hemasphere
. 2024 Aug;
8(8):e130.
PMID: 39175824
CD19-directed autologous chimeric antigen receptor T cell (CAR-T) therapy has transformed the management of relapsed/refractory (R/R) large B cell lymphoma (LBCL). Initially approved in the third line and beyond setting,...
10.
Hershenfeld S, Tobin J, Shelton V, Calvente L, Lajkosz K, Liu T, et al.
Br J Haematol
. 2024 Aug;
205(5):1810-1814.
PMID: 39112220
Radiotherapy is routinely used for management of limited-stage follicular lymphoma (FL), yet half of patients ultimately relapse. We hypothesized that the presence of specific gene mutations may predict outcomes. We...